FDA to discuss Xeljanz sNDAs in psoriatic arthritis, accepts UC sNDA

FDA’s Arthritis Advisory Committee will meet on Aug. 3 to discuss sNDAs from Pfizer Inc. (NYSE:PFE) for Xeljanz (Jaquinus) tofacitinib and Xeljanz XR extended release to treat adults with active psoriatic arthritis.

Pfizer said FDA accepted the sNDAs for review in May. At the time, Pfizer said the anticipated PDUFA date for the sNDAs would be in December. ...